Biotech Today: Arrowhead Research Corp (ARWR), Gilead Sciences (GILD), MannKind Corporation (MNKD), Biocept (BIOC), Synergy Pharmaceuticals (SGYP)

Arrowhead Research Corp Climbs On Earnings | More Gains To Come

Arrowhead Research Corp (NASDAQ: ARWR)

Arrowhead Research Corp is having an incredible day in the market today after reporting strong Q3 earnings. While the company did produce a loss, as expected from biotech stocks in its phase, the loss was $0.11 less than analysts expected to see. However, that’s not the only news investors should be focused on. As a matter of fact, tomorrow, ARWR will be giving a presentation at a Jefferies conference. Many experts, including myself, believe that this is going to be another catalyst that sends the stock climbing. Currently (1:06), ARWR is trading at $6.87 per share after a gain of 13.98% so far today. Considering that the Jefferies conference presentation is likely to lead to more gains, investors may want to think about getting in today!

Gilead Sciences Nears Support | The Sky Is The Limit

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences is one of my favorite stocks in the biotech space; and for good reason. The company has complete control over the HCV treatment market; and while AbbVie has stepped in to take a piece of the pie, it hasn’t led to ill effects for GILD. Currently, the stock is trading at an incredible discount; but I’m not sure that’s going to last for much longer. Lately, we’ve seen gains from the stock as it pushes closer and closer to a breakout. This one is definitely one to watch; if it breaks resistance, we can expect a very strong and profitable run!

MannKind Corporation Continues As The Battle Field

MannKind Corporation (NASDAQ: MNKD)

MannKind Corporation is a stock that I believe is one of the best representations of the battle between the bears and the bulls. That’s because if you look into the details, you can see that both sides are right; it all depends on the amount of time investors give MNKD to grow. In the short run, both the bears and the bulls know that MNKD isn’t likely to see any massive gains. However, in the long run, Afrezza is likely to drive incredible profits. Not to mention that the technosphere technology is almost guaranteed to lead to more innovations in medicine. Currently (1:13), MNKD is trading at $4.12 per share after a loss of 0.60% so far today. However, if you’re into long term investing, this is one that you may want to strongly consider looking into!

Biocept Climbs On New Liquid Biopsy Announcement

Biocept, Inc. (NASDAQ: BIOC)

Biocept is having a strong day today after announcing the launch of the first liquid biopsy diagnostic test for colorectal cancer. The testis a proprietary quantitative Target Selector which targets KRAS mutations through the use of a simple blood sample. This new test will help physicians identify patients who may benefit from targeted therapies that are currently available to treat solid tumor cancers. The test also may be used for the monitory of patients for responses to treatments and progression of the disease during the course of therapy. Currently (1:21), BIOC is trading at $2.40 per share after a gain of 3.80% so far today.

Synergy Pharmaceuticals Is Seeing Red | Not For Long

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals isn’t having the best of days in the market today. However, I don’t think that the declines are likely to last very long. Recently, SGYP has been trading up and down, but staying in a clear range between $9.45 and $7.91 per share. While it may continue to fall today, I’m expecting to see gains tomorrow to make up for it. Unfortunately, the shorts are taking control of the stock at the moment. However, I don’t think that’s likely to last long. The reality is that SGYP is most likely going to realize regulatory approval for plecanatide. So, when the NDA is submitted, we’re likely to see massive growth. For many investors, that can’t happen soon enough!

Image Credit

Add Comment